JP2005519891A - 危篤状態の患者における罹病率および死亡率を低下させる方法 - Google Patents

危篤状態の患者における罹病率および死亡率を低下させる方法 Download PDF

Info

Publication number
JP2005519891A
JP2005519891A JP2003559435A JP2003559435A JP2005519891A JP 2005519891 A JP2005519891 A JP 2005519891A JP 2003559435 A JP2003559435 A JP 2003559435A JP 2003559435 A JP2003559435 A JP 2003559435A JP 2005519891 A JP2005519891 A JP 2005519891A
Authority
JP
Japan
Prior art keywords
fgf
critically ill
ill patients
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003559435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519891A5 (https=
Inventor
ジョゼフ・ジョージ・ヒューアー
アレクセイ・カリトネンコフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2005519891A publication Critical patent/JP2005519891A/ja
Publication of JP2005519891A5 publication Critical patent/JP2005519891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2003559435A 2002-01-15 2003-01-08 危篤状態の患者における罹病率および死亡率を低下させる方法 Pending JP2005519891A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34889002P 2002-01-15 2002-01-15
PCT/US2003/000010 WO2003059270A2 (en) 2002-01-15 2003-01-08 Method for reducing morbidity and mortality in critically ill patients

Publications (2)

Publication Number Publication Date
JP2005519891A true JP2005519891A (ja) 2005-07-07
JP2005519891A5 JP2005519891A5 (https=) 2006-02-23

Family

ID=23370005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559435A Pending JP2005519891A (ja) 2002-01-15 2003-01-08 危篤状態の患者における罹病率および死亡率を低下させる方法

Country Status (6)

Country Link
US (1) US20050176631A1 (https=)
EP (1) EP1469880A4 (https=)
JP (1) JP2005519891A (https=)
AU (1) AU2003201810A1 (https=)
CA (1) CA2468610A1 (https=)
WO (1) WO2003059270A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP2270163A1 (en) * 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP2014500248A (ja) 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
BR112014014898A2 (pt) 2011-12-22 2020-10-27 Pfizer Inc. processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
JP2018135329A (ja) * 2018-02-19 2018-08-30 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイド塩及びそれらの使用
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3876996A1 (en) 2018-11-05 2021-09-15 Bristol-Myers Squibb Company Method for purifying pegylated protein
EP4087612A1 (en) 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163626A1 (en) * 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20020081663A1 (en) * 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20020151496A1 (en) * 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
US20040259780A1 (en) * 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity

Also Published As

Publication number Publication date
WO2003059270A2 (en) 2003-07-24
AU2003201810A8 (en) 2003-07-30
US20050176631A1 (en) 2005-08-11
WO2003059270A3 (en) 2003-11-27
EP1469880A2 (en) 2004-10-27
CA2468610A1 (en) 2003-07-24
AU2003201810A1 (en) 2003-07-30
EP1469880A4 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
JP2005519891A (ja) 危篤状態の患者における罹病率および死亡率を低下させる方法
EP0639079B1 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JPWO2018186480A1 (ja) 線維性疾患の治療薬
US20050250684A1 (en) Method for reducing morbidity and mortality in critically ill patients
CA2462543A1 (en) Glucagon-like peptides (glp-1) and treatment of respiratory distress
CN112279920B (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
JPWO2006115274A1 (ja) 骨髄赤血球前駆細胞分化促進剤
CN113248628A (zh) 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
JP2000511190A (ja) 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
Hatton et al. Systemic metabolic effects of combined insulin-like growth factor–I and growth hormone therapy in patients who have sustained acute traumatic brain injury
Boden et al. An islet cell carcinoma containing glucagon and insulin: chronic glucagon excess and glucose homeostasis
KR20070008519A (ko) 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
US11844771B2 (en) Methods of treating acute respiratory distress syndrome using colchicine
JPH06510292A (ja) 慢性肝疾患治療剤
CN105431165A (zh) 用于治疗心肺手术后的术后并发症的组合物和方法
JP4463885B2 (ja) 劇症肝炎疾患治療剤
US6303127B1 (en) Treatment of disease states
Pawlik et al. Central role of interleukin-6 in burn induced stimulation of hepatic amino acid transport
KR20000065178A (ko) 허혈-재관류손상을치료또는예방하는방법
JP7016125B2 (ja) 脳梗塞の治療薬
US20070141053A1 (en) Treatment of inflammatory respiratory diseases
JP2010509364A (ja) 創傷治癒における使用のためのｉｌ−１７ｂ
Manjunathan et al. Biodiversity of the Adipocyte-Derived Hormone, Leptin
EP1608396B1 (en) Use of soluble cd14 for treatment of diseases
CN116999538A (zh) 一种治疗细胞因子风暴的药物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090623